-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3778 Mathematical Modeling to Identify Clotting Factor Combinations That Modify Thrombin Generation in Hemophilia

Program: Oral and Poster Abstracts
Session: 321. Coagulation and Fibrinolysis: Basic and Translational: Poster III
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Bleeding and Clotting, hemophilia, Diseases
Monday, December 12, 2022, 6:00 PM-8:00 PM

Michael Stobb1*, Dougald Monroe, PhD2, Keith B. Neeves, PhD3, Suzanne Sindi4*, Aaron Fogelson5* and Karin Leiderman6*

1Coe College, Cedar Rapids, IA
2Hematology and Oncology, School of Medicine, University of North Carolina, Chapel Hill, NC
3Departments of Bioengineering and Pediatrics, University of Colorado Denver, Aurora, CO
4University of California Merced, Merced, CA
5University of Utah, Salt Lake City, UT
6University of North Carolina, Chapel Hill, Chapel Hill

Background: In previous work, we used our mathematical model to identify modifiers of thrombin generation in hemophilia A (Link, JTH, 18, 2020). We performed thousands of simulations that varied clotting factors and inhibitors between 50 and 150% of their baseline plasma levels. From those simulations, we identified the combinations of factors and inhibitors that led to enhanced thrombin generation. We found that factor V (FV), at low normal levels (50%-75%), was a major contributor of the thrombin enhancement. The model elucidated an underlying mechanism to be substrate competition between factors V and VIII for activated factor X (FXa), which occurred early in the thrombin generation process. That study was focused on hemophilia A.

Aims: To identify factor combinations that enhance or attenuate thrombin generation in mild, moderate, and severe hemophilia A, B, and C.

Methods: Plasma levels for factors II, V, VII, VIII, IX, X, XI, tissue factor pathway inhibitor (TFPI), and antithrombin (AT) were fixed at one of three values: 50%, 100%, or 150% of normal. We simulated all possible combinations of these three factor levels for normal blood, and mild, moderate, and severe hemophilia A, B, and C type blood, characterized by deficiencies of 10, 5, and 1% of normal plasma levels. For each combination of factor levels, tissue factor (TF) was varied, and combinations of factor levels were identified as thrombin enhancing (or attenuating) when they resulted in at least a 10-fold increase (or decrease) in detectable thrombin levels. We used an updated version of our mathematical model that includes interactions between TFPI and partially cleaved FV.

Results: For simulations of severe hemophilia A and B, combinations of low normal levels (50%) of FV and TFPI and high normal levels (150%) of FII and FX lead to an increase in total thrombin. Interestingly, the opposite combinations (high normal FV and TFPI, low normal FII and FX) led to a decrease in total thrombin for simulations of mild hemophilia A and B. In some of the severe deficiency cases, high normal FVIII levels in hemophilia B and low normal FIX levels in hemophilia A were found to enhance thrombin generation. In normal blood and hemophilia C, combinations of low normal levels (50%) of FV and TFPI and high normal levels (150%) of FVIII and FIX led to an increase in total thrombin, and again the opposite levels attenuated thrombin generation. In some cases, low normal levels of AT also enhanced thrombin generation.

Conclusion(s): Our mathematical model identified new and testable combinations of parameters that enhance thrombin generation in severe hemophilia and attenuated thrombin generation in mild hemophilia.

Disclosures: Monroe: Sanofi: Research Funding. Leiderman: Novo Nordisk: Research Funding.

*signifies non-member of ASH